EC
VRDN icon

EcoR1 Capital’s Viridian Therapeutics VRDN Stock Holding History

EcoR1 Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,958,847
Closed -$44.6M – 72
2024
Q3 		$44.6M Buy
+1,958,847
New +$32M 1.53% 16

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

EcoR1 Capital's VRDN Position: Q4 2024 in Review

EcoR1 Capital sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 1,958,847 shares — an estimated $44.6M sold.

EcoR1 Capital first reported a position in VRDN in Q3 2024 and held it in 1 quarter. The position peaked at $44.6M in Q3 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • EcoR1 Capital reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EcoR1 Capital sold 1,958,847 Viridian Therapeutics shares in Q4 2024, an estimated $44.6M.
  • EcoR1 Capital first reported a position in Viridian Therapeutics in Q3 2024 and held it in 1 quarter.
  • EcoR1 Capital's Viridian Therapeutics position peaked at $44.6M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on EcoR1 Capital's 13F filing for Q4 2024, filed 14 Feb 2025.